USING PHARMACOECONOMIC MODELLING TO DETERMINE VALUE-BASED PRICING FOR NEW MEDICINES
Purpose: to carry out pharmacoeconomic modeling for an early economic evaluation of the generic pegylated liposomal doxorubicin (PLD) drug.Materials and methods: a Markov model and Decision tree model were developed to simulate and to compare the costs and effects of new generic PLD versus doxorubic...
Saved in:
| Main Authors: | I. S. KRYSANOV, V. Yu. ERMAKOVA, A. V. ZABOROVSKY, K. G. GUREVICH |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Healthcare of the Russian Federation. “Kuban State Medical University”
2017-05-01
|
| Series: | Кубанский научный медицинский вестник |
| Subjects: | |
| Online Access: | https://ksma.elpub.ru/jour/article/view/670 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Public Innovation Policy in the Pharmaceutical Industry: the Cases of the EU and USA
by: Z. A. Mamedyarov
Published: (2017-04-01) -
An assessment of Information disclosures by Pharmaceutical Industry: Evidence from India
by: Rupali Khanna, et al.
Published: (2019-10-01) -
Pervasive systemic disparities: medical-related gaslighting, trauma, and distrust among LGBTQ+ people in the United States
by: Dustin Z. Nowaskie, et al.
Published: (2025-02-01) -
PHARMA SUPPLY CHAIN RESILIENCE. A SYSTEMATIC REVIEW
by: Balázs Bence Dienes, et al.
Published: (2024-06-01) -
Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer
by: E. V. Artamonova
Published: (2016-09-01)